What determines GLP-1 eligibility

Eligibility is not one number

Some FDA-approved weight-management products describe labeled populations by obesity or overweight with at least one weight-related condition. Current Wegovy labeling separates injection and tablet populations. Wegovy injection is labeled for weight reduction and long-term maintenance in adults and pediatric patients aged 12 years and older with obesity, and adults with overweight plus at least one weight-related condition. Wegovy tablets are labeled for weight reduction and long-term maintenance in adults with obesity, or adults with overweight plus at least one weight-related condition DailyMed Wegovy label. Zepbound labeling describes adult weight reduction and long-term maintenance uses with diet and physical activity DailyMed Zepbound label.

Those label details are only part of the decision. The clinician still reviews risk factors, contraindications and whether another care path is safer.

What can affect clinical fit

• Personal or family history of medullary thyroid carcinoma or MEN 2.
• Serious hypersensitivity to semaglutide, tirzepatide or product excipients.
• Pregnancy, breastfeeding questions, pregnancy plans and contraception. Wegovy labeling says weight loss offers no benefit during pregnancy and may cause fetal harm, and recommends discontinuing at least 2 months before planned pregnancy for weight reduction or cardiovascular risk reduction. Zepbound labeling includes discontinuation guidance when pregnancy is recognized and gives oral-contraceptive precautions after starting and dose escalation Wegovy label Zepbound label.
• History of pancreatitis, gallbladder disease, severe gastrointestinal problems or kidney issues.
• Use of insulin, sulfonylureas or other medicines that can affect hypoglycemia risk.
• Current symptoms that need in-person or urgent evaluation.
• Ability to complete follow-up, report side effects and handle medication instructions safely.

This list is not a self-screening tool. It is a preview of the kinds of topics worth bringing to the clinician.

Follow-up fit is part of eligibility

Eligibility also includes whether the care plan can be monitored. A clinician may need to know that the patient can report side effects, complete follow-up visits, understand medication instructions and get labs or in-person care when needed. A prescription without follow-up can leave important safety questions unanswered.

Patients can help by being direct about travel, pharmacy access, cost concerns, side effects from past medication and whether they already have a primary-care clinician. Those details can shape a practical plan.

Approval status can affect the eligibility discussion

If a program discusses compounded medication, eligibility should include a product-sourcing conversation. FDA says compounded GLP-1 drugs are not FDA-approved, are not generic versions of FDA-approved drugs and should not be marketed as having the same proven result as an approved product FDA telehealth compounding reminders.

FDA also says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug FDA concerns with unapproved GLP-1 drugs. That is why patients should ask what medical need a compounded preparation is addressing.

Good questions to ask

• Which product label are you using to judge fit?
• What in my health history makes this appropriate or inappropriate?
• What side effects should prompt me to contact the care team?
• Will any of my current medications need monitoring?
• Could labs, records or a primary-care visit change the decision?

If treatment is not appropriate, read what can happen when treatment is not appropriate. If treatment is appropriate, read how refills and follow-up may work.

Common questions